Iyun, 2025-Yil
209
THE ROLE OF ENDOTHELIAL DYSFUNCTION IN THE PATHOGENESIS AND
PROGRESSION OF CARDIOVASCULAR DISEASES: DIAGNOSTIC AND
THERAPEUTIC PERSPECTIVES
¹Baxrillayev Yusufxon Matlubovich
²Boltayev Xusan Bahodir o‘g‘li
³Ergashov Davlatjon G‘ayratjon o‘g‘li
¹'²'³Samarkand State Medical University DKTF, Department of Internal Medicine, Cardiology and
Functional Diagnostics! Second-year clinical residents.
https://doi.org/10.5281/zenodo.15637745
Research objective
Endothelial dysfunction is a critical early event in the pathogenesis of atherosclerosis and
other cardiovascular diseases (CVDs). It serves not only as a marker of vascular health but also as
a mediator of disease progression, impacting vascular tone, platelet aggregation, leukocyte
adhesion, and thrombogenesis. The objective of this research is to provide a comprehensive
analysis of the mechanisms underlying endothelial dysfunction, its role in the development and
progression of cardiovascular pathologies, the methods available for its assessment, and current as
well as emerging therapeutic strategies aimed at restoring endothelial function.
Introduction
The endothelium is a monolayer of cells lining the inner surface of blood vessels, serving
as a dynamic interface between circulating blood and vascular smooth muscle. It regulates
vascular tone through the balanced release of vasodilators, such as nitric oxide (NO), prostacyclin,
and endothelium-derived hyperpolarizing factor, and vasoconstrictors like endothelin-1,
angiotensin II, and thromboxane A2. In a healthy state, the endothelium maintains an anti-
inflammatory, anti-thrombotic, and anti-proliferative environment. However, under pathological
conditions such as hypertension, hyperlipidemia, smoking, diabetes mellitus, and chronic
inflammation, endothelial cells undergo phenotypic changes characterized by decreased
bioavailability of NO and increased oxidative stress, inflammation, and cellular apoptosis.
Nitric oxide, produced by endothelial nitric oxide synthase (eNOS), is pivotal in
maintaining vascular homeostasis. In dysfunctional endothelium, eNOS becomes uncoupled due
to substrate or cofactor deficiency, resulting in the generation of superoxide rather than NO. This
leads to a state of oxidative stress that further degrades NO and promotes peroxynitrite formation,
causing cellular damage and impairing endothelial-dependent vasodilation. Simultaneously,
upregulation of pro-inflammatory cytokines (e.g., TNF-α, IL-6), adhesion molecules (VCAM-1,
ICAM-1, E-selectin), and chemokines (MCP-1) enhances leukocyte adhesion and transmigration,
fostering a pro-atherogenic milieu.
Materials and Methods
Endothelial dysfunction precedes structural changes such as intimal thickening, vascular
remodeling, and plaque formation. It plays a pivotal role in initiating and accelerating
atherosclerosis by facilitating lipoprotein infiltration and oxidation, smooth muscle proliferation,
and extracellular matrix remodeling. In coronary artery disease (CAD), endothelial dysfunction is
associated with impaired coronary flow reserve and increased risk of myocardial ischemia.
Iyun, 2025-Yil
210
In heart failure with preserved ejection fraction (HFpEF), systemic endothelial dysfunction
contributes to myocardial stiffening and microvascular rarefaction. Similarly, in peripheral arterial
disease (PAD), cerebrovascular disease, and pulmonary hypertension, endothelial impairment
exacerbates vascular resistance and tissue hypoxia.
Results
Numerous non-invasive and invasive methods have been developed to assess endothelial
function. Flow-mediated dilation (FMD) of the brachial artery using high-resolution ultrasound is
a widely used non-invasive technique. Other approaches include peripheral arterial tonometry
(EndoPAT), laser Doppler flowmetry, and measurement of circulating biomarkers such as
asymmetric dimethylarginine (ADMA), von Willebrand factor, and endothelial microparticles.
Invasive methods such as acetylcholine-induced vasodilation assessed during coronary
angiography remain the gold standard for coronary endothelial function evaluation.
Therapeutic strategies targeting endothelial dysfunction include both lifestyle interventions
and pharmacological treatments. Lifestyle modifications such as smoking cessation, dietary
changes (e.g., Mediterranean diet rich in polyphenols and omega-3 fatty acids), regular physical
activity, weight loss, and stress reduction have shown to significantly improve endothelial
function. Pharmacologically, statins not only lower LDL-C but also exert pleiotropic effects
including upregulation of eNOS and attenuation of oxidative stress. ACE inhibitors and ARBs
reduce angiotensin II-mediated vasoconstriction and inflammation while increasing NO
bioavailability. Beta-blockers such as nebivolol, with NO-potentiating properties, and calcium
channel blockers improve endothelial-dependent vasodilation.
Conclusion
: Emerging therapies focus on restoring endothelial homeostasis at the
molecular level. Agents such as tetrahydrobiopterin (BH4), an essential eNOS cofactor, have been
investigated to prevent eNOS uncoupling. Antioxidants like vitamin C, vitamin E, and N-
acetylcysteine aim to reduce oxidative stress, though clinical results have been inconsistent. Anti-
inflammatory biologics targeting IL-1β (e.g., canakinumab) and TNF-α are under investigation for
their vascular protective roles. Gene therapy to enhance eNOS expression or deliver anti-
inflammatory cytokines offers a futuristic approach to endothelial restoration.
The gut microbiota-endothelium axis is an emerging field revealing the impact of
microbial metabolites such as trimethylamine-N-oxide (TMAO) on endothelial health. Diet-
induced dysbiosis increases TMAO levels, promoting inflammation and oxidative stress.
Probiotics, prebiotics, and dietary modulation are being studied for their potential to restore
microbiome balance and improve endothelial function. Additionally, novel biomarkers such as
circulating microRNAs (e.g., miR-126, miR-92a) and exosomal proteins are being explored for
their diagnostic and prognostic utility in endothelial dysfunction.
In conclusion, endothelial dysfunction is a key initiator and amplifier of cardiovascular
diseases. Its early detection and targeted management are essential for preventing vascular
complications and improving cardiovascular outcomes. A combination of lifestyle interventions,
pharmacological therapies, and emerging molecular strategies hold promise for restoring
endothelial health and halting the progression of CVD.
Iyun, 2025-Yil
211
REFERENCES
1.
Andryev S. et al. Experience with the use of memantine in the treatment of cognitive
disorders //Science and innovation. – 2023. – Т. 2. – №. D11. – С. 282-288.
2.
Antsiborov S. et al. Association of dopaminergic receptors of peripheral blood
lymphocytes with a risk of developing antipsychotic extrapyramidal diseases //Science and
innovation. – 2023. – Т. 2. – №. D11. – С. 29-35.
3.
Asanova R. et al. Features of the treatment of patients with mental disorders and
cardiovascular pathology //Science and innovation. – 2023. – Т. 2. – №. D12. – С. 545-
550.
4.
Begbudiyev M. et al. Integration of psychiatric care into primary care //Science and
innovation. – 2023. – Т. 2. – №. D12. – С. 551-557.
5.
Bo’Riyev B. et al. Features of clinical and psychopathological examination of young
children //Science and innovation. – 2023. – Т. 2. – №. D12. – С. 558-563.
6.
Borisova Y. et al. Concomitant mental disorders and social functioning of adults with
high-functioning autism/asperger syndrome //Science and innovation. – 2023. – Т. 2. – №.
D11. – С. 36-41.
7.
Ivanovich U. A. et al. Efficacy and tolerance of pharmacotherapy with antidepressants in
non-psychotic depressions in combination with chronic brain ischemia //Science and
Innovation. – 2023. – Т. 2. – №. 12. – С. 409-414.
8.
Nikolaevich R. A. et al. Comparative effectiveness of treatment of somatoform diseases in
psychotherapeutic practice //Science and Innovation. – 2023. – Т. 2. – №. 12. – С. 898-
903.
9.
Novikov A. et al. Alcohol dependence and manifestation of autoagressive behavior in
patients of different types //Science and innovation. – 2023. – Т. 2. – №. D11. – С. 413-
419.
10.
Pachulia Y. et al. Assessment of the effect of psychopathic disorders on the dynamics of
withdrawal syndrome in synthetic cannabinoid addiction //Science and innovation. – 2023.
– Т. 2. – №. D12. – С. 240-244.
11.
Pachulia Y. et al. Neurobiological indicators of clinical status and prognosis of therapeutic
response in patients with paroxysmal schizophrenia //Science and innovation. – 2023. – Т.
2. – №. D12. – С. 385-391.
12.
Pogosov A. et al. Multidisciplinary approach to the rehabilitation of patients with
somatized personality development //Science and innovation. – 2023. – Т. 2. – №. D12. –
С. 245-251.
13.
Pogosov A. et al. Rational choice of pharmacotherapy for senile dementia //Science and
innovation. – 2023. – Т. 2. – №. D12. – С. 230-235.
14.
Pogosov S. et al. Gnostic disorders and their compensation in neuropsychological
syndrome of vascular cognitive disorders in old age //Science and innovation. – 2023. – Т.
2. – №. D12. – С. 258-264.
15.
Pogosov S. et al. Prevention of adolescent drug abuse and prevention of yatrogenia during
prophylaxis //Science and innovation. – 2023. – Т. 2. – №. D12. – С. 392-397.
Iyun, 2025-Yil
212
16.
Pogosov S. et al. Psychogenetic properties of drug patients as risk factors for the formation
of addiction //Science and innovation. – 2023. – Т. 2. – №. D12. – С. 186-191.
17.
Prostyakova N. et al. Changes in the postpsychotic period after acute polymorphic disorder
//Science and innovation. – 2023. – Т. 2. – №. D12. – С. 356-360.
18.
Prostyakova N. et al. Issues of professional ethics in the treatment and management of
patients with late dementia //Science and innovation. – 2023. – Т. 2. – №. D12. – С. 158-
165.
19.
Prostyakova N. et al. Sadness and loss reactions as a risk of forming a relationship together
//Science and innovation. – 2023. – Т. 2. – №. D12. – С. 252-257.
20.
Prostyakova N. et al. Strategy for early diagnosis with cardiovascular diseaseisomatized
mental disorders //Science and innovation. – 2023. – Т. 2. – №. D12. – С. 166-172.
21.
Rotanov A. et al. Comparative effectiveness of treatment of somatoform diseases in
psychotherapeutic practice //Science and innovation. – 2023. – Т. 2. – №. D12. – С. 267-
272.
22.
Rotanov A. et al. Diagnosis of depressive and suicidal spectrum disorders in students of a
secondary special education institution //Science and innovation. – 2023. – Т. 2. – №. D11.
– С. 309-315.
23.
Rotanov A. et al. Elderly epilepsy: neurophysiological aspects of non-psychotic mental
disorders //Science and innovation. – 2023. – Т. 2. – №. D12. – С. 192-197.
24.
Rotanov A. et al. Social, socio-cultural and behavioral risk factors for the spread of hiv
infection //Science and innovation. – 2023. – Т. 2. – №. D11. – С. 49-55.
25.
Rotanov A. et al. Suicide and epidemiology and risk factors in oncological diseases
//Science and innovation. – 2023. – Т. 2. – №. D12. – С. 398-403.
26.
Sedenkov V. et al. Clinical and socio-demographic characteristics of elderly patients with
suicide attempts //Science and innovation. – 2023. – Т. 2. – №. D12. – С. 273-277.
27.
Sedenkov V. et al. Modern methods of diagnosing depressive disorders in neurotic and
affective disorders //Science and innovation. – 2023. – Т. 2. – №. D12. – С. 361-366.
28.
Sedenkova M. et al. Basic principles of organizing gerontopsychiatric assistance and their
advantages //Science and innovation. – 2023. – Т. 2. – №. D11. – С. 63-69.
29.
Sedenkova M. et al. Features of primary and secondary cognitive functions characteristic
of dementia with delirium //Science and innovation. – 2023. – Т. 2. – №. D11. – С. 56-62.
30.
Sedenkova M. et al. The possibility of predicting the time of formation and development of
alcohol dependence: the role of genetic risk, family weight and its level //Science and
innovation. – 2023. – Т. 2. – №. D12. – С. 173-178.
31.
Shamilov V. et al. Disorders of decision-making in the case of depression: clinical
evaluation and correlation with eeg indicators //Science and innovation. – 2023. – Т. 2. –
№. D12. – С. 198-204.
32.
Solovyova Y. et al. Protective-adaptive complexes with codependency //Science and
innovation. – 2023. – Т. 2. – №. D11. – С. 70-75.
33.
Solovyova Y. et al. Suicide prevention in adolescents with mental disorders //Science and
innovation. – 2023. – Т. 2. – №. D11. – С. 303-308.
Iyun, 2025-Yil
213
34.
Solovyova Y. et al. The relevance of psychotic disorders in the acute period of a stroke
//Science and innovation. – 2023. – Т. 2. – №. D12. – С. 212-217.
35.
Spirkina M. et al. Integrated approach to correcting neurocognitive defects in
schizophrenia //Science and innovation. – 2023. – Т. 2. – №. D11. – С. 76-81.
